---
title: "FOXO Technologies Signs Series E Preferred Stock Exchange Agreement With Rennova Health"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275179726.md"
description: "FOXO Technologies has signed a Series E Preferred Stock Exchange Agreement with Rennova Health to convert $200,000 in cash advances into equity. The company will issue 8,000 shares of Series E Cumulative Redeemable Secured Preferred Stock at $25.00 per share, fully satisfying and cancelling the prior advances. This private placement agreement was effective on December 31, 2025, allowing FOXO to extinguish debt and convert short-term advances to preferred equity."
datetime: "2026-02-06T22:13:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275179726.md)
  - [en](https://longbridge.com/en/news/275179726.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275179726.md)
---

# FOXO Technologies Signs Series E Preferred Stock Exchange Agreement With Rennova Health

FOXO Technologies entered into a Series E Preferred Stock Exchange Agreement to convert $200,000 of prior cash advances from Rennova Health into equity. The company will issue 8,000 shares of Series E Cumulative Redeemable Secured Preferred Stock at a stated value of $25.00 per share. Upon issuance, the prior advances will be fully satisfied and cancelled, and Rennova will no longer have creditor rights related to those advances. The transaction was made as a private placement to an accredited investor.

**Agreement details:**

-   **Agreement type**: Series E Preferred Stock Exchange Agreement
-   **Counterparty**: Rennova Health
-   **Signed / Effective**: Feb 06 2026 / Dec 31 2025
-   **Duration / Termination**: At will
-   **Reason**: Convert short-term advances to preferred equity and extinguish debt

Original SEC Filing: FOXO TECHNOLOGIES INC. \[ FOXO \] - 8-K - Feb. 06, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [FOXO.US](https://longbridge.com/en/quote/FOXO.US.md)
- [IHF.US](https://longbridge.com/en/quote/IHF.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FOXOW.US](https://longbridge.com/en/quote/FOXOW.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [RNVA.US](https://longbridge.com/en/quote/RNVA.US.md)
- [XHS.US](https://longbridge.com/en/quote/XHS.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [Medicare Advantage Company Alignment Healthcare Shows Huge, Unusual Call Option Activity](https://longbridge.com/en/news/287101232.md)
- [Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery](https://longbridge.com/en/news/287100303.md)
- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study | DWTX Stock News](https://longbridge.com/en/news/286772955.md)
- [UnitedHealth Group Incorporated $UNH Holdings Boosted by GSA Capital Partners LLP](https://longbridge.com/en/news/286878927.md)